Category

1. Chemical carcinogenesis and radiation carcinogenesis

1-1	Activation and metabolism of carcinogens
1-2	Detection and assessment of carcinogens
1-3	DNA damage
1-4	Process of carcinogenesis
1-5	Nitric oxide/reactive oxygen
1-6	Genotoxins and nongenotoxins
1-7	Experimental cell culture systems
1-8	Radiation and electromagnetic wave carcinogenesis
1-9	Others

2. Experimental animal models and genetically-engineered animals

2-1	Gene-manipulated animal models
2-2	Animal model for carcinogenesis
2-3	Patient-derived experimental model
2-4	Others

3. Virus, infection, inflammation and cancer

3-1	EBV
3-2	HPV
3-3	HBV
3-4	HCV
3-5	HTLV-1
3-6	HHV-8
3-7	H.pylori
3-8	Other viruses/bacteria
3-9	Intestinal bacteria/microbiome
3-10	Inflammation and cancer

4. Oncogenes and tumor-suppressor genes

4-1	ras family genes
4-2	p53-related genes
4-3	Rb/p16-related genes
4-4	Wnt signaling-related genes
4-5	Chromosomal translocation-related genes
4-6	Other oncogenes/tumor-suppressor genes
4-7	Novel oncogenes/tumor-suppressor genes

5. Signal transduction and gene expression

5-1	Proliferation/differentiation
5-2	Signal transduction
5-3	Transcriptional regulation
5-4	Translational regulation
5-5	RNA engineering
5-6	ncRNA・microRNA
5-7	Others

6. DNA replication/cell cycle/
genomic instability

6-1	Cell cycle/checkpoint
6-2	DNA replication
6-3	DNA repair
6-4	Genetic instability

7. Cancer genome/genetics

7-1	Genomic analysis
7-2	Genomic medicine
7-3	NGS
7-4	Genome editing
7-5	Homozygous deletion/positional cloning
7-6	Chromosomal translocation/gene rearrangement
7-7	Gene amplification
7-8	Familial tumor and target genes
7-9	Carcinogenic sensitivity-related genes (SNPs)
7-10	Others

8. Cell death/immortalization

8-1	Cell death
8-2	Telomere/senescence/immnortalization
8-3	Others

9. Epigenetics

9-1	DNA methylation
9-2	Histone modification
9-3	Chromatin structure
9-4	Others

10. Invasion and metastasis

10-1	Cell adhesion/invasion
10-2	Extracellular matrices and proteases
10-3	Metastasis-associated genes
10-4	Angiogenesis
10-5	Diagnosis of metastasis
10-6	Metastasis inhibition
10-7	Metastasis models
10-8	Others

11. Characteristics of cancer cells

11-1	Cancer stem cellｓ
11-2	Cell differentiation
11-3	Cell-to-cell interaction/adhesion molecules
11-4	Cell lines
11-5	Organoid
11-6	Carbohydrate chains and glycosyltransferases
11-7	Extracellular vesicles/Exosome
11-8	Metabolism / Metabolome
11-9	Others

12. Cancer immunity

12-1	Innate immunity
12-2	Dendritic cells/antigen-presenting cells
12-3	Tumor antigens
12-4	Antitumor effector cells and their induction
12-5	Immune checkpoint inhibitors
12-6	Vaccination therapy
12-7	Antibody therapy
12-8	Other immunotherapies
12-9	Others

13. Growth factors/cytokines/hormones

13-1	Growth- and differentiation-regulating factors
13-2	Growth factor receptors
13-3	Hormones
13-4	Cytokines
13-5	TGF-b/Smad

14. Cancer basic, diagnosis and treatment

14-1	Gastric cancer
14-2	Esophageal cancer
14-3	Colorectal cancer
14-4	GIST
14-5	Hepatocellular cancer
14-6	Carcinoma of the biliary tract
14-7	Pancreatic cancer
14-8	Lung cancer
14-9	Breast cancer
14-10	Uterine cancer
14-11	Ovarian cancer
14-12	hematopoietic malignancy
14-13	Ｒenal cell cancer
14-14	Bladder cancer
14-15	Prostatic cancer
14-16	Testicular cancer
14-17	Brain tumor
14-18	Primary bone tumor
14-19	Soft tissue sarcoma
14-20	Head and neck cancer
14-21	Endocrine cancer
14-22	Skin cancer
14-23	Childhood cancer/AYA
14-24	Other organs

15. Diagnosis

15-1	Pathological diagnosis
15-2	Diagnostic imaging
15-3	Diagnosis by tumor markers and biomarkers
15-4	Genomic diagnostics
15-5	Diagnosis by expression analysis (mRNA, protein)
15-6	Novel diagnostic technology
15-7	Liquid biopsy
15-8	Artificial intelligence based diagnostics
15-9	Others

16. Molecular-targeting therapy

16-1	Signal transduction inhibitors/kinase inhibitors
16-2	Angiogenesis inhibitors/antimetastatic drugs
16-3	Cell cycle inhibitors (CDK inhibitors etc.)
16-4	Transcription modulators (histone deacetylase inhibitors etc.)
16-5	Others

17. Chemotherapy and endocrine therapy

17-1	Natural anticancer compounds
17-2	Synthetic anticancer compounds
17-3	DNA-damaging drug (Platinum compounds/Topoisomerase inhibitors etc.)
17-4	Antimetabolites
17-5	Antimicrotubular drugs (taxane/alkaloids etc.)
17-6	Anticancer drug resistance
17-7	Anticancer drug and cell death
17-8	Endocrine therapy
17-9	Differentiation-inducing therapy
17-10	Drug delivery system
17-11	Combinational therapy/adjuvant therapy
17-12	Others

18. Evaluation and prediction of pharmacological effects

18-1	Drug sensitivity/drug resistance-relating factors/gene expression analysis
18-2	Pharmacokinetics/pharmacodynamics (PK/PD)
18-3	Pharmacogenomics/toxicogenomics (SNPs, transcriptome, proteome)
18-4	Sensitivity test
18-5	Clinical trial
18-6	Biobank

19. Radiation therapy

19-1	Radiation and particle ray therapy
19-2	Radiation hazard/protection
19-3	Radiosensitivity
19-4	Efficacy enhancement
19-5	Hyperthermia
19-6	Others

20. Cell therapy and regeneration medicine

20-1	Stem cells
20-2	Regenerative medicine
20-3	Cell therapy of allograft
20-4	Others

21. Gene therapy

21-1	Generation and modification of vectors
21-2	Immunogenetic therapy
21-3	Oncogene/tumor-suppressor gene therapy
21-4	Suicide gene therapy
21-5	Nucleic acid therapeutics (including DDS)
21-6	Others

22. Medical care of progressive cancer

22-1	Psychooncology
22-2	Palliative treatment and care
22-3	Others

23. Cancer prevention/chemoprevention

23-1	Mechanism of cacinogenesis inhibition
23-2	Synthetic compounds
23-3	Natural products
23-4	Dietary/alimentary factors
23-5	Others

24. Epidemiology

24-1	Environmental factors (life habits etc.)/infectious exposure
24-2	Cancer prone syndromes/molecular epidemiology
24-3	Cohort study
24-4	Descriptive epidemiology/cancer registration
24-5	Cancer screening
24-6	Others

25. Information/informatics

25-1	Bioinfomatics
25-2	Management and analysis of cancer patients' data
25-3	Others

26. Cancer and society

26-1	Informed consent
26-2	Bioethics
26-3	Social movement against cancer
26-4	Smoking and drinking alcohol
26-5	Others